Case Study on T-DM1 (Kadcyla)

Service Pages

Questions?

Home 5 Service 5 Case Study on T-DM1 (Kadcyla)

Trastuzumab-DM1 (T-DM1; biosimilar of Kadcyla®) was synthesized and was tested in an in vitro efficacy assay employing an in vivo xenograft model.

The following results demonstrate the in-house T-DM1 has comparable tumor inhibition activity and in vivo PK profiles comparing to reported data of Kadcyla. 

Acute toxicity of T-DM1 was assessed. Results showed tested ADC products are well tolerated at the tested dosages

In vivo efficacy results from T-DM1 case study using NCl-N87 gastric cancer xenograft model. Data showed full regression of tumor after treatment with 15mg/kg of ADC.

Headquarters

1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203

w

Contact Us

China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000
Japan: +81 03 5403 6975

contact@chempartner.com